InvestorsHub Logo
Followers 466
Posts 26950
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 2151

Thursday, 03/22/2012 8:54:14 AM

Thursday, March 22, 2012 8:54:14 AM

Post# of 2237
7:30AM POZEN announces preliminary top-line results from two pivotal Phase 3 studies of PA32540: primary and secondary endpoints met (POZN) 4.80 : PA32540 is a novel, coordinated-delivery tablet of immediate-release omeprazole (40 mg) and delayed release aspirin (325 mg). The two Phase 3 pivotal trials were randomized, double-blind, multi-center studies in which a total of 1,049 subjects at risk for developing aspirin-associated ulcers and already taking aspirin at a dose of 325 mg once daily for at least three months for secondary prevention of cardiovascular events were randomly assigned to treatment with either PA32540 or 325 mg enteric-coated aspirin once daily. The primary endpoint, a significant reduction in the cumulative incidence of gastric ulcers following administration of PA32540 vs. 325 mg enteric-coated aspirin over six months, was met in both studies. Additionally, the studies met their key secondary endpoints, including a reduction in gastroduodenal ulceration as well as a reduction in discontinuation due to upper gastrointestinal adverse events in subjects taking PA32540 compared to 325 mg enteric-coated aspirin. Reported adverse events were consistent with the trial population and the known adverse event profile of aspirin and omeprazole. Further analyses of the data will be conducted, and presentation of the data at an appropriate upcoming scientific meeting, as well as publication of the full results, is planned.


surf's up......crikey